New developments in the prophylaxis and treatment of graft versus host disease

Expert Opinion on Pharmacotherapy

Volumn 2, Issue 7, 2001, Pages 1109-1117

  Simpson, D ^a  

^a NORTH SHORE HOSPITAL   (New Zealand)

Author keywords

Allogeneic; Bone marrow transplant; Graft versus host disease

Indexed keywords

15 DEOXYSPERGUALIN; ALEMTUZUMAB; AZATHIOPRINE; CYCLOSPORIN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; ETANERCEPT; FLUDARABINE; GLYCOPROTEIN GP 39; IMMUNOPHILIN; INFLIXIMAB; INTERLEUKIN 2 RECEPTOR ANTIBODY; MELPHALAN; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY; TUMOR NECROSIS FACTOR;

ALLOGENIC BONE MARROW TRANSPLANTATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DONOR; DRUG CHOICE; GINGIVA HYPERPLASIA; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; IMMUNOLOGICAL TOLERANCE; LEUKOPENIA; LYMPHOCYTE DEPLETION; NEPHROTOXICITY; ORGAN TRANSPLANTATION; ORTHOSTATIC HYPOTENSION; PERIPHERAL BLOOD STEM CELL; REVIEW; STEROID THERAPY; T LYMPHOCYTE; THROMBOCYTOPENIA; TREMOR;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION; ANTIMETABOLITES; BONE MARROW TRANSPLANTATION; CD40 LIGAND; CLINICAL TRIALS; CYCLOSPORINE; DRUG DESIGN; GRAFT VS HOST DISEASE; GUANIDINES; GUIDELINES; HUMANS; IMMUNOCONJUGATES; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; METHOTREXATE; MYCOPHENOLIC ACID; SIROLIMUS; T-LYMPHOCYTES; TACROLIMUS;

EID: 0034941907     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.2.7.1109     Document Type: Review

References (68)

1. Tolerating differences
2. Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation
3. Mycophenolate mofetil and its mechanisms of action
4. Mycophenolate mofetil
5. Mycophenolate mofetil in renal transplantation: Results from the U.S. randomized trials
6. The European experience with mycophenolate mofetil
7. Rescue therapy with Mycophenolate mofetil
8. Mycophenolate mofetil in cadaveric renal transplantation
9. Synergism between Mycophenolate mofetil and cyclosporine in preventing graft-versus-host disease among lethally irradiated dogs given DLA-nonidentical unrelated marrow grafts
10. Administration of Mycophenolate mofetil in a murine model of acute graft-versus-host disease after bone marrow transplantation
11. Mycophenolate mofetil and cyclosporine as graft-versus-host disease prophylaxis after allogeneic blood stem cell transplantation
12. Outpatient allografting with minimally myelosuppressive, immunosuppressive conditioning of low-dose TBI and postgrafting cyclosporine and Mycophenolate mofetil
13. Salvage therapy for refractory chronic graft-versus-host disease with Mycophenolate mofetil and tacrolimus
14. Mycophenolate mofetil (Mycophenolate mofetil) as therapy for refractory chronic GVHD (cGVHD) in children receiving bone marrow transplantation
15. Immunophilins and the nervous system
16. Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes
17. Two distinct action mechanisms of immunophilin-ligand complexes for the blockade of T-cell activation
18. Phase III study comparing tacrolimus (FK506) with cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors
19. FK506 (Tacrolimus) monotherapy for prevention of graft-versus-host disease after histocompatible sibling allogeneic bone marrow transplantation
20. FK506 in combination with methotrexate for the prevention of graft- versus-host disease after marrow transplantation from matched unrelated donors
21. Tacrolimus and minidose methotrexate for prevention of acute graft-versus-host disease after matched unrelated donor marrow transplantation
22. Tacrolimus and minidose methotrexate for prevention of acute graft-versus-host disease after HLA-mismatched marrow or blood stem cell transplantation
23. Rapamune (RAPA, rapamycin, sirolimus): Mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression
24. Rapamune (Sirolimus, rapamycin): An overview and mechanism of action
25. Mechanism of action of rapamycin: New insights into the regulation of G1-phase progression in eukaryotic cells
26. Sirolimus (rapamycin)-based therapy in human renal transplantation: Similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group
27. Immunosuppressive effects and safety of a sirolimus/cyclosporine combination regimen for renal transplantation
28. Sirolimus-tacrolimus combination immunosuppression [letter]
29. Blocking both signal 1 and signal 2 of T-cell activation prevents apoptosis of alloreactive T cells and induction of peripheral allograft tolerance
30. Graft-versus-host disease prevention by rapamycin: Cellular mechanisms
31. Rapamycin induces long term marrow chimerism in the absence of long term immunosuppression in mismatched stem cell transplantation: Application to sickle cell mice
32. Minimizing graft rejection in allogeneic T cell-depleted bone marrow transplantation
33. T-cell depletion of bone marrow transplants for leukemia from donors other than HLA-identical siblings: Advantage of T-cell antibodies with narrow specificities
34. Potent effects of ATG used as part of the conditioning in matched unrelated donor transplantation
35. Evaluation of non-myeloablative conditioning combining BEAM with in-vivo pre-transplant Campath-1G for allogeneic transplantation in patients with lymphoma
36. CAMPATH-1 monoclonal antibodies in bone marrow transplantation
37. In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation
38. A randomized, double-blinded comparison of thymoglobulin versus Atgam for induction immunosuppressive therapy in adult renal transplant recipients
39. Treatment of steroid-resistant acute graft-versus-host disease with rabbit antithymocyte globulin
40. Graft tolerance: A duel of two signals
41. The new immunology - The end of immunosuppressive drug therapy?
42. Blocking OX-40/OX-40 ligand interaction in vitro and in vivo leads to decreased T cell function and amelioration of experimental allergic encephalomyelitis
43. CD28-B7 blockade after alloantigenic challenge in vivo inhibits Th1 cytokines but spares Th2
44. Long-term acceptance of major histocompatibility complex mismatched cardiac allografts induced by CTLA4Ig plus donor-specific transfusion
45. CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates
46. Transplantation of anergic histoincompatible bone marrow allografts
47. Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates
48. CD4(+) T cells tolerized ex vivo to host alloantigen by anti-CD40 ligand (CD40L:CD154) antibody lose their graft-versus-host disease lethality capacity but retain nominal antigen responses
49. Pharmacokinetics/dynamics of 5c8, a monoclonal antibody to CD154 (CD40 ligand) suppression of an immune response in monkeys
50. Absence of platelet CD40L identifies patients with X-linked hyper IgM syndrome
51. Phase I study of NKT-01
52. LF 08-0299 induces tolerance after short-term treatment in a fully major histocompatibility mismatched rat cardiac allograft model
53. Tolerance in a rat cardiac allograft model after short-term treatment with LF 08-0299. Absence of clonal deletion and evidence of CD4+ suppressor cells
54. Analysis of in vivo immunosuppressive and in vitro interaction with constitutive heat shock protein 70 activity of LF08-0299 (Tresperimus) and analogues
55. A review of interleukin-2 receptor antagonists in solid organ transplantation
56. Population pharmacokinetics and exposure-response relationships for basiliximab in kidney transplantation. The U.S. Simulect Renal Transplant Study Group
57. Basiliximab
58. Use of an anti-interleukin-2 receptor monoclonal antibody for GVHD prophylaxis in unrelated donor BMT
59. Prophylaxis of graft-versus-host disease by administration of the murine anti-IL-2 receptor antibody 2A3
60. Impairment of leukaemia-free survival by addition of interleukin-2-receptor antibody to standard graft-versus-host prophylaxis
61. A phase II/III randomized, double blind, placebo-controlled multicenter trial of humanized anti-TAC for prevention of acute graft-versus-host disease in recipients of marrow transplants from unrelated donors
62. Daclizumab, a humanized anti-interleukin-2 receptor alpha chain antibody, for treatment of acute graft-versus-host disease
63. Basiliximab - A selective interleukin-2 receptor antagonist - As therapy for refractory acute graft-versus-host disease following bone marrow transplantation
64. An old drug for a new disease: Pentostatin (Nipent) in acute graft-versus-host disease
65. Pentostatin: A novel treatment for steroid refractory acute GVHD
66. Infliximab for the treatment of graft-versus-host disease in allogeneic transplant recipients: An update
67. Recombinant human soluble tumor necrosis factor receptor fusion protein (Enbrel) as a treatment for chronic graft-versus-host disease following allogeneic bone marrow transplantation
68. Hydroxychloroquine for the treatment of chronic graft-versus-host disease